A Phase 3 interventional study of TAK-625 in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Takeda. Completed at 8 sites in Japan. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of the study is to check if TAK-625 improves symptoms of Progressive Familial Intrahepatic Cholestasis (PFIC), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.
The participants will be treated with TAK-625 for up to the end of study (about 34 months).
Participants will visit their study clinic 15 times from the start of study. After 15 times visits, participants will visit their study clinic every 12 weeks up to the end of study.
33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.
This study's enrollment of 5 is below the median of 60 across 11 interventional studies indexed under Cholestasis, progressive familial intrahepatic 1.
Browse Cholestasis, progressive familial intrahepatic 1 studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) based on:
Chronic cholestasis as manifested by persistent (>6 months*) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease. (* =\<6 months is acceptable for participants \<12 months of age).
AND
For Primary cohort:
a) The participant has a genetic testing result consistent with disease-causing variation in ABCB11 (PFIC2), based on a genotyping.
For Supplemental cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.
Drug: TAK-625
TAK-625 orally, twice daily (BID) for 4 weeks as Dose Escalation Period. The dose in Dose Escalation Period will be increased weekly, 150 mcg/kilograms (kg), 300 mcg/kg, 450 mcg/kg, and 600 mcg/kg. After Dose Escalation Period, TAK-625 600 mcg/kg (or maximum tolerated dose \[MTD\]), orally, BID up to study completion.
Drug: TAK-625
TAK-625 orally, twice daily (BID)
Also known as: Maralixibat chloride
Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26
The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Average baseline morning ItchRO (Obs) scores were calculated as sum of the morning scores divided by number of morning scores for the 4-week (28 days) time periods (that is \[i.e.\], Day -28 to Day -1). Average morning ItchRO (Obs) scores Week 15 through Week 26 were calculated as the sum of the morning scores divided by the number of morning scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
Time frame: Baseline to Week 15 through Week 26
Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26
The ItchRO (Obs) scale measures frequency of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1= A little bit of the time, 2= Some of the time, 3= Most of the time, 4= Almost all of the time/constantly, I don't know) to describe their pruritus condition. 'I don't know' was categorized as missing data. A higher score indicated more severe pruritus. Baseline average morning ItchRO (Obs) frequency scores were calculated as the sum of the morning frequency scores divided by the number of morning severity scores for the 4-week (28 days) time periods. (i.e., Day -28 to Day -1). Average morning ItchRO (Obs) frequency scores of Week 15 through Week 26 were calculated as the sum of the morning frequency scores divided by the number of mornings frequency scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
Time frame: Baseline to Week 15 through Week 26
Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26
Change from baseline was calculated as: Post-baseline observed value - Baseline (before first dosing) observed value. Change from baseline in total sBA levels to Week 26 was reported.
Time frame: Baseline to Week 26
Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 26
Responders to sBA control were defined as participants who achieved a decrease to less than (\<) 102 mcmol/L, a decrease of greater than (\>) 75 percentage (%), or normalization at any timepoint from baseline through Week 26.
Time frame: Baseline through Week 26
Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26
ItchRO (Obs) scale measures severity of pruritus, score ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity was calculated based on daily maximum severity scores from both morning and evening. Average baseline morning and evening ItchRO (Obs) scores were calculated as sum of morning or evening scores divided by number of morning or evening scores for 4-week (28 days) time periods (i.e., Day -28 to Day -1). Average morning and evening ItchRO (Obs) scores Week 15 to Week 26 were calculated as sum of morning or evening scores divided by number of morning or evening scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
Time frame: Baseline to Week 15 through Week 26
Participants took part in the study at 8 sites in Japan from 10 January 2023 to 22 July 2025.
| Milestone | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Started | 3 | 2 |
| Dosed tak-625 150 mcg/kg | 3 | 2 |
| Dosed tak-625 300 mcg/kg | 3 | 2 |
| Dosed tak-625 450 mcg/kg | 3 | 2 |
| Dosed tak-625 600 mcg/kg | 3 | 2 |
| Completed | 3 | 2 |
| Not completed | 0 | 0 |
The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Average baseline morning ItchRO (Obs) scores were calculated as sum of the morning scores divided by number of morning scores for the 4-week (28 days) time periods (that is \[i.e.\], Day -28 to Day -1). Average morning ItchRO (Obs) scores Week 15 through Week 26 were calculated as the sum of the morning scores divided by the number of morning scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
| score on a scale | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26 | -1.514 (-3.6541 to 0.6255) | -0.202 (-3.6957 to 3.2911) |
The ItchRO (Obs) scale measures frequency of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1= A little bit of the time, 2= Some of the time, 3= Most of the time, 4= Almost all of the time/constantly, I don't know) to describe their pruritus condition. 'I don't know' was categorized as missing data. A higher score indicated more severe pruritus. Baseline average morning ItchRO (Obs) frequency scores were calculated as the sum of the morning frequency scores divided by the number of morning severity scores for the 4-week (28 days) time periods. (i.e., Day -28 to Day -1). Average morning ItchRO (Obs) frequency scores of Week 15 through Week 26 were calculated as the sum of the morning frequency scores divided by the number of mornings frequency scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
| score on a scale | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Change in the Average Morning ItchRO (Obs) Frequency Score Between Baseline and the Average of Week 15 Through Week 26 | -0.740 (-4.8063 to 3.3254) | -0.735 (-6.0922 to 4.6213) |
Change from baseline was calculated as: Post-baseline observed value - Baseline (before first dosing) observed value. Change from baseline in total sBA levels to Week 26 was reported.
| micromoles per liter (mcmol/L) | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Change From Baseline in Total Serum Bile Acid (sBA) Levels to Week 26 | -149.900 (-561.4008 to 261.6008) | -18.250 (-173.9010 to 137.4010) |
Responders to sBA control were defined as participants who achieved a decrease to less than (\<) 102 mcmol/L, a decrease of greater than (\>) 75 percentage (%), or normalization at any timepoint from baseline through Week 26.
| percentage of participants | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Percentage of Participants (Responders) Who Experienced an sBA Control From Baseline Through Week 26 | 33.3 (0.84 to 90.57) | 0.0 (0.00 to 84.19) |
ItchRO (Obs) scale measures severity of pruritus, score ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity was calculated based on daily maximum severity scores from both morning and evening. Average baseline morning and evening ItchRO (Obs) scores were calculated as sum of morning or evening scores divided by number of morning or evening scores for 4-week (28 days) time periods (i.e., Day -28 to Day -1). Average morning and evening ItchRO (Obs) scores Week 15 to Week 26 were calculated as sum of morning or evening scores divided by number of morning or evening scores from Week 15 to Week 26. Change was calculated as: Average value of Weeks 15 to 26 - Average value of Baseline (Day -28 to Day -1).
| score on a scale | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| Change in the ItchRO (Obs) Weekly Average Severity Between Baseline and the Average of Week 15 Through Week 26 | -1.629 (-3.5064 to 0.2481) | -0.254 (-4.3906 to 3.8824) |
Collected over From start of study drug administration up to follow-up (up to Week 133). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary Cohort: TAK-625 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Supplemental Cohort: TAK-625 | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 |
|---|---|---|
| COVID-19Infections and infestations | 1/3 | 2/2 |
| Upper respiratory tract infectionInfections and infestations | 3/3 | 2/2 |
| DermatitisSkin and subcutaneous tissue disorders | 2/3 | 0/2 |
| NasopharyngitisInfections and infestations | 2/3 | 1/2 |
| Abdominal pain upperGastrointestinal disorders | 0/3 | 1/2 |
| Auricular haematomaInjury, poisoning and procedural complications | 0/3 | 1/2 |
| Blood bilirubin increasedInvestigations | 0/3 | 1/2 |
| ConstipationGastrointestinal disorders | 0/3 | 1/2 |
| GastroenteritisInfections and infestations | 0/3 | 1/2 |
| GingivitisInfections and infestations | 0/3 | 1/2 |
Intention-to-treat (ITT) included all participants who received at least one dose of study drug. As per-planned analysis, the cohort-wise (primary and supplemental) data were analyzed, collected, and reported in this study.
| Age, Continuous(years) | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 | Total |
|---|---|---|---|
| Mean | 7.7 ± 3.21 | 8.0 ± 4.24 | 7.8 ± 3.11 |
| Sex: Female, Male(Participants) | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Primary Cohort: TAK-625 | Supplemental Cohort: TAK-625 | Total |
|---|---|---|---|
| Asian | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).
Ran from Jan 2023 to primary completion in Sep 2023, 7 months.
Results were first posted in Sep 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat
Cholestasis, progressive familial intrahepatic 1 →